Form4insider filings, from the source

SEC Form 4 · accession 0001127602-19-005984

LABCORP HOLDINGS INC. · LH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
John D Ratliff
Officer — CEO, Covance Drug Development
Period of report
Feb 12, 2019
Accepted (ET)
Feb 14, 2019 · 4:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000920148

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Feb 12, 2019M1,463—A16,255D
Common StockFeb 12, 2019F654$146.59D15,601D
Common Stockholding———40IBy revocable trust
Common StockF3holding———80IBy irrevocable trust

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Restricted Stock UnitF5,F1,F4—Feb 12, 2019M1,463D——Common Stock1,46316,911D
Restricted Stock UnitF5,F1,F6—Feb 12, 2019A5,300A——Common Stock5,30022,211D
Non-qualified Stock OptionsF7,F8$146.59Feb 12, 2019A21,800AFeb 12, 2020Feb 11, 2029Common Stock21,80021,800D

Explanation of responses